Related Experiment Video
Updated: Mar 29, 2026

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
One-year Real-world Outcomes With Faricimab in Neovascular Age-related Macular Degeneration
David C Tabano1, Ferhina S Ali2, Durga S Borkar3,4
1Genentech, South San Francisco, California.
Background And Objective:
This study evaluated real-world treatment patterns and 1-year outcomes in patients with neovascular age-related macular degeneration (nAMD) initiating faricimab.
Patients And Methods:
FARETINA-AMD was a retrospective study using data from the IRIS® Registry for patients diagnosed with nAMD initiating faricimab from February 2022 to March 2023.
Results:
Included in the study were 2,025 treatment-naive patients (2,184 eyes) and 22,253 patients (26,851 eyes) previously treated with anti-vascular endothelial growth factor (anti-VEGF) therapy. Visual acuity improved by 2.0 ± 15.0 (mean ± SD) letters in treatment-naive eyes (P < .001) and was maintained in previously treated eyes at injection 7. Central subfield thickness (CST) improved by -53.1 ± 64.8 μm in treatment-naive and -28.5 ± 79.7 μm in previously treated eyes (both P < .0001); 78.4% and 66.8%, respectively, had achieved/maintained CST ≤ 280 μm at injection 7. Dosing frequency was reduced in the second 6 months (mean 2.4-3.2 injections) versus the first 6 months (4.0-4.2) of treatment.
Conclusion:
Outcomes among patients with nAMD receiving faricimab over 1-year follow-up support the real-world effectiveness and extended durability of treatment.
More Related Videos
07:04Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
10:24Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
FDA Approved Drugs: Changes to Approved Drugs
Angle Closure Glaucoma: Treatment
Pharmacodynamics in Geriatric Patients: Effects of Age